StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
BLSMBlossomHill Therapeutics, Inc.
stockpulse.co.kr
Nasdaq
$14.55▲ 0.45%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

5
  • 9.18Pre-market26.09.18 20:30
    10-QEarnings#●●●#●●●#●●●

    BlossomHill Therapeutics, Inc.

    BlossomHill Therapeutics has filed its quarterly report (Form 10-Q) for the period ended June 30, 2026. As of September 16, 2026, the company has 31,784,909 shares of common stock outstanding and is actively developing its product candidates, including BH-30643, BH-30236, and BH-501284.…more

    $14.55+0.45%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 9.18Pre-market26.09.18 20:15
    8-KKey event

    BlossomHill Therapeutics, Inc.

    BlossomHill Therapeutics reported a net loss of $23.76 million for the second quarter of 2026 and strengthened its balance sheet by raising $168.3 million in gross proceeds from its August IPO. The company's lead candidate, BH-30643, received FDA Fast Track designation, and the company expects its current cash position to fund operations into the second quarter of 2028.…more

    $14.55+0.45%vs prev close
    View filingShare
  • 9.15Pre-market26.09.15 20:30
    8-KKey event

    BlossomHill Therapeutics, Inc.

    BlossomHill Therapeutics announced updated Phase 1/2 clinical trial data for its NSCLC candidate BH-30643. The drug demonstrated a 45% objective response rate and an 88% disease control rate in patients with EGFR C797S mutations, with plans to initiate a global Phase 2 study in Q1 2027.…more

    $14.55+0.45%vs prev close
    View filingShare

4 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 3d agoPre-market26.10.22 20:00
    #●●●#●●●#●●●

    BlossomHill Therapeutics Partners with Foundation Medicine for Lung Cancer Diagnostic…more

    BlossomHill Therapeutics has partnered with Foundation Medicine to develop a companion diagnostic for its lung cancer drug candidate, BH-30643. This collaboration aims to validate the assay while supporting the ongoing clinical development of the drug for EGFR-mutated non-small cell lung cancer.…more

    $14.55+0.45%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    Read sourceShareGlobeNewswire
  • 9.28Pre-market26.09.28 20:00

    ●●●●●●●● ●●●●● ●●●●●●

    BlossomHill Therapeutics presented preclinical data for its novel pan-KRAS inhibitor, demonstrating potent antitumor activity in various cancer models. The company plans to submit an IND application in the first quarter of 2027 to advance the program.…more

    $14.55+0.45%vs prev close
    Read sourceShareGlobeNewswire
  • 9.18Pre-market26.09.18 20:11

    ●●●●●●●● ●●●●● ●●●●●●

    BlossomHill Therapeutics is scheduled to report its second-quarter earnings before the market opens on September 18. Investors should monitor the upcoming financial results for potential stock price movement.…more

    $14.55+0.45%vs prev close
    ShareBenzinga

2 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →